Last reviewed · How we verify
Urokinase thrombolysis
Urokinase thrombolysis works by activating plasminogen to plasmin, which breaks down blood clots.
Urokinase thrombolysis works by activating plasminogen to plasmin, which breaks down blood clots. Used for Acute ischemic stroke, Pulmonary embolism.
At a glance
| Generic name | Urokinase thrombolysis |
|---|---|
| Also known as | Urokinase |
| Sponsor | Capital Medical University |
| Drug class | Fibrinolytic agent |
| Target | Plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This process involves the conversion of plasminogen to plasmin, which then degrades fibrin clots. Urokinase is a type of tissue plasminogen activator (tPA) that plays a crucial role in the fibrinolytic pathway. By activating plasminogen, urokinase helps to dissolve blood clots and restore blood flow.
Approved indications
- Acute ischemic stroke
- Pulmonary embolism
Common side effects
- Hemorrhage
- Allergic reactions
- Fever
- Nausea and vomiting
Key clinical trials
- TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage (NA)
- Urokinase for Thrombolysis in Acute Ischemic Stroke (NA)
- Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) (NA)
- 'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL (NA)
- The MRI-based Evaluation of Safety and Efficacy of EVT and SMT: A Retrospective, Multicenter Study
- CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II (PHASE2)
- Thrombolysis of Urokinase for Minor Stroke (PHASE3)
- The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Urokinase thrombolysis CI brief — competitive landscape report
- Urokinase thrombolysis updates RSS · CI watch RSS
- Capital Medical University portfolio CI